Applied BioCodeTPE:6598 74 EBIT per Share is NT$-1.95 as of Dec. 2025. GuruFocus rates TPE:6598 with a GF Score™ of 74/100 and a GF Value™ of NT$23.34 (Fairly Valued). The stock has 6 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Applied BioCode ranks worse than 62.65% on this metric.
Applied BioCode's EBIT per Share for the
three
months ended in Dec. 2025 was NT$-0.62.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.95.
During the past 3 years, the average EBIT per Share Growth Rate was 0.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -8.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Applied BioCode's EBIT per Share or its related term are showing as below:
TPE:6598'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -17.1 Med: 1.3 Max: 32.8
Current: 0.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Applied BioCode was 32.80% per year. The lowest was -17.10% per year. And the median was 1.30% per year.
TPE:6598's 3-Year EBIT Growth Rate is ranked worse than 62.65% of 688
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs TPE:6598: 0.80
Applied BioCode's EBIT for the
three
months ended in Dec. 2025 was NT$-63.4 Mil.
Applied BioCode (TPE:6598) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Applied BioCode EBIT per Share Related Terms
Applied BioCode EBIT per Share Historical Data
* Premium members only.
The historical data trend for Applied BioCode's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1.95
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Applied BioCode (TPE:6598) has a EBIT per Share of NT$-1.95 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Applied BioCode and its competitors. According to the industry distribution chart, Applied BioCode ranks #431 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 62.6%.
Is Applied BioCode's EBIT per Share too high?
Applied BioCode's current EBIT per Share is NT$-1.95. Based on the distribution chart, Applied BioCode ranks #431 out of 688 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Applied BioCode has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Applied BioCode ranks #431 out of 688 companies for EBIT per Share. This places Applied BioCode in the lower half of its industry. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Applied BioCode and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Applied BioCode's current EBIT per Share is NT$-1.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Fairly Valued. The stock's GF Value™ is NT$23.34, compared to a current price of NT$22.85 — trading 2.1% below its estimated fair value. The current EBIT per Share is NT$-1.95. Applied BioCode's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current EBIT per Share is NT$-1.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Applied BioCode (TPE:6598) Overvalued in 2026?
Based on GuruFocus' analysis, Applied BioCode stock appears to be undervalued.
The current stock price of NT$22.85 is trading 2.1% below its estimated GF Value™ of NT$23.34.
GuruFocus considers Applied BioCode to be Fairly Valued.
Key valuation signals for TPE:6598:
EBIT per Share: NT$-1.95
GF Value™: NT$23.34 vs. price of NT$22.85 (2.1% below fair value)
No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
74GF Score
Get the complete analysis for TPE:6598
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6598 has been successfully added to your 
